Skip to main content

Table 2 Comparative risk of cardiorenal outcomes among 1:1 PS-matched initiators of empagliflozin vs. GLP-1RA

From: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

 

Empagliflozin

GLP-1RA

Empagliflozin vs. GLP-1RA

Primary and secondary outcomes

N events (IR/1,000 PY)

N events (IR/1,000 PY)

HR (95% CI)

RD/1,000PY (95% CI)

Empagliflozin vs. GLP-1RA (N of matched pairs = 141,541)

Primary outcomes

 Composite of myocardial infarction or stroke

1317 (13.12)

1274 (13.35)

0.99 (0.92, 1.07)

-0.23 (-1.25, 0.79)

 Hospitalization for heart failure

507 (5.03)

700 (7.31)

0.69 (0.62, 0.77)

-2.28 (-2.98, -1.59)

 MACE*†

854 (22.6)

922 (25.14)

0.90 (0.82, 0.99)

-2.54 (-4.76, -0.32)

 Composite of cardiovascular mortality or hospitalization for heart failure†

540 (14.22)

675 (18.34)

0.77 (0.69, 0.86)

-4.11 (-5.95, -2.29)

Secondary outcomes

    

 Composite of primary outcomes (all databases)‡

1757 (17.54)

1881 (19.77)

0.89 (0.84, 0.95)

-2.23 (-3.45, -1.02)

 Composite of primary outcomes (Medicare)§

1158 (30.75)

1305 (35.76)

0.86 (0.79, 0.93)

-5.01 (-7.65, -2.39)

 Hospitalization for heart failure (broad)||

2301 (23.02)

2600 (27.44)

0.85 (0.80, 0.90)

-4.42 (-5.83, -3.01)

 Myocardial infarction

813 (8.08)

815 (8.52)

0.95 (0.86, 1.05)

-0.44 (-1.25, 0.36)

 Stroke

522 (5.18)

466 (4.86)

1.08 (0.95, 1.22)

0.32 (-0.31, 0.94)

 Cardiovascular mortality†

202 (5.3)

242 (6.54)

0.81 (0.67, 0.97)

-1.24 (-2.34, -0.14)

 All-cause mortality †

517 (13.57)

570 (15.4)

0.88 (0.78, 0.99)

-1.83 (-3.56, -0.11)

 Unstable angina

263 (2.61)

259 (2.7)

0.96 (0.81, 1.14)

-0.09 (-0.55, 0.36)

 Coronary revascularization

990 (9.86)

958 (10.03)

0.99 (0.90, 1.08)

-0.17 (-1.06, 0.71)

 ESKD#

128 (19.73)

180 (26.5)

0.75 (0.60, 0.94)

-6.77 (-11.97, -1.61)

  1. ESKD: end-stage kidney disease; PS: propensity score; IR: Incidence rate; PY: person-years; HR: hazard ratio; CI: confidence intervals; RD: rate difference
  2. * MACE includes hospitalizations for myocardial infarction, stroke, or cardiovascular mortality
  3. † Only available in the Medicare database (54,292 1:1 PS-matched pairs)
  4. ‡ Includes hospitalizations for myocardial infarction, stroke, or heart failure
  5. § Includes hospitalizations for myocardial infarction, stroke, cardiovascular mortality, or heart failure
  6. || Includes hospitalization for heart failure in all discharge positions
  7. # Restricted to patients with chronic kidney disease stages 3–4 (10,837 1:1 PS-matched pairs)
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840